Active surveillance for low-risk prostate cancer

Chris H. Bangma, Meelan Bul, Theo H. van der Kwast, Tom Pickles, Ida J. Korfage, Caroline M. Hoeks, Ewout W. Steyerberg, Guido Jenster, Michael W. Kattan, Lara Bellardita, Peter R. Carroll, Louis J. Denis, Chris Parker, Monique J. Roobol, Mark Emberton, Laurence H. Klotz, Antti Rannikko, Yoshiyuki Kakehi, Janet A. Lane, Fritz H. Schröder & 3 others Axel Semjonow, Bruce Trock, Riccardo Valdagni

Research output: Contribution to journalArticle

Abstract

Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference " Active Surveillance for low risk prostate cancer" (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.

Original languageEnglish (US)
Pages (from-to)295-302
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume85
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Prostatic Neoplasms
Patient Care
Netherlands
Patient Selection
Neoplasms
Biomarkers
Quality of Life
Technology
Growth
Research
Direction compound
Therapeutics
Medical Overuse

Keywords

  • Active surveillance
  • Biomarkers
  • Imaging
  • Nomograms
  • Overdiagnosis
  • Prostate cancer
  • Screening

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Bangma, C. H., Bul, M., van der Kwast, T. H., Pickles, T., Korfage, I. J., Hoeks, C. M., ... Valdagni, R. (2013). Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology, 85(3), 295-302. https://doi.org/10.1016/j.critrevonc.2012.07.005

Active surveillance for low-risk prostate cancer. / Bangma, Chris H.; Bul, Meelan; van der Kwast, Theo H.; Pickles, Tom; Korfage, Ida J.; Hoeks, Caroline M.; Steyerberg, Ewout W.; Jenster, Guido; Kattan, Michael W.; Bellardita, Lara; Carroll, Peter R.; Denis, Louis J.; Parker, Chris; Roobol, Monique J.; Emberton, Mark; Klotz, Laurence H.; Rannikko, Antti; Kakehi, Yoshiyuki; Lane, Janet A.; Schröder, Fritz H.; Semjonow, Axel; Trock, Bruce; Valdagni, Riccardo.

In: Critical Reviews in Oncology/Hematology, Vol. 85, No. 3, 03.2013, p. 295-302.

Research output: Contribution to journalArticle

Bangma, CH, Bul, M, van der Kwast, TH, Pickles, T, Korfage, IJ, Hoeks, CM, Steyerberg, EW, Jenster, G, Kattan, MW, Bellardita, L, Carroll, PR, Denis, LJ, Parker, C, Roobol, MJ, Emberton, M, Klotz, LH, Rannikko, A, Kakehi, Y, Lane, JA, Schröder, FH, Semjonow, A, Trock, B & Valdagni, R 2013, 'Active surveillance for low-risk prostate cancer', Critical Reviews in Oncology/Hematology, vol. 85, no. 3, pp. 295-302. https://doi.org/10.1016/j.critrevonc.2012.07.005
Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM et al. Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology. 2013 Mar;85(3):295-302. https://doi.org/10.1016/j.critrevonc.2012.07.005
Bangma, Chris H. ; Bul, Meelan ; van der Kwast, Theo H. ; Pickles, Tom ; Korfage, Ida J. ; Hoeks, Caroline M. ; Steyerberg, Ewout W. ; Jenster, Guido ; Kattan, Michael W. ; Bellardita, Lara ; Carroll, Peter R. ; Denis, Louis J. ; Parker, Chris ; Roobol, Monique J. ; Emberton, Mark ; Klotz, Laurence H. ; Rannikko, Antti ; Kakehi, Yoshiyuki ; Lane, Janet A. ; Schröder, Fritz H. ; Semjonow, Axel ; Trock, Bruce ; Valdagni, Riccardo. / Active surveillance for low-risk prostate cancer. In: Critical Reviews in Oncology/Hematology. 2013 ; Vol. 85, No. 3. pp. 295-302.
@article{212bc3f4d461458e81f428a137eaaabe,
title = "Active surveillance for low-risk prostate cancer",
abstract = "Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference {"} Active Surveillance for low risk prostate cancer{"} (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.",
keywords = "Active surveillance, Biomarkers, Imaging, Nomograms, Overdiagnosis, Prostate cancer, Screening",
author = "Bangma, {Chris H.} and Meelan Bul and {van der Kwast}, {Theo H.} and Tom Pickles and Korfage, {Ida J.} and Hoeks, {Caroline M.} and Steyerberg, {Ewout W.} and Guido Jenster and Kattan, {Michael W.} and Lara Bellardita and Carroll, {Peter R.} and Denis, {Louis J.} and Chris Parker and Roobol, {Monique J.} and Mark Emberton and Klotz, {Laurence H.} and Antti Rannikko and Yoshiyuki Kakehi and Lane, {Janet A.} and Schr{\"o}der, {Fritz H.} and Axel Semjonow and Bruce Trock and Riccardo Valdagni",
year = "2013",
month = "3",
doi = "10.1016/j.critrevonc.2012.07.005",
language = "English (US)",
volume = "85",
pages = "295--302",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Active surveillance for low-risk prostate cancer

AU - Bangma, Chris H.

AU - Bul, Meelan

AU - van der Kwast, Theo H.

AU - Pickles, Tom

AU - Korfage, Ida J.

AU - Hoeks, Caroline M.

AU - Steyerberg, Ewout W.

AU - Jenster, Guido

AU - Kattan, Michael W.

AU - Bellardita, Lara

AU - Carroll, Peter R.

AU - Denis, Louis J.

AU - Parker, Chris

AU - Roobol, Monique J.

AU - Emberton, Mark

AU - Klotz, Laurence H.

AU - Rannikko, Antti

AU - Kakehi, Yoshiyuki

AU - Lane, Janet A.

AU - Schröder, Fritz H.

AU - Semjonow, Axel

AU - Trock, Bruce

AU - Valdagni, Riccardo

PY - 2013/3

Y1 - 2013/3

N2 - Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference " Active Surveillance for low risk prostate cancer" (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.

AB - Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference " Active Surveillance for low risk prostate cancer" (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.

KW - Active surveillance

KW - Biomarkers

KW - Imaging

KW - Nomograms

KW - Overdiagnosis

KW - Prostate cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84873522061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873522061&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2012.07.005

DO - 10.1016/j.critrevonc.2012.07.005

M3 - Article

VL - 85

SP - 295

EP - 302

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -